Inside the GLP-1 Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Mini-deep dive on the fastest growing healthcare opportunity from an investment and health perspective This is for: Science enthusiasts Pharma/biotech consultants, analysts Investors in the life science space Doctors, nutritionists, health coaches, fitness coaches People considering or already on weight loss medication Longevity enthusiasts I help you: Understand what weight loss medications are Get a list of the key obesity players in the pharma/biotech space Understand lifestyle strategies to get the best outcomes out of GLP1s Free Resources included: Obesity development landscape and launch timelines Weight loss data from key drugs in development Comment Health and I will share a US market model template to help you forecast weight loss drug sales yourself See inside for disclosure Intro to Weight Loss Medications (WLMs) Unless you are living under a rock, the words GLP1, Ozempic, Wegovy, Mounjaro, weight-loss medication must not be new to you
Clinical outcomes (change in HbA 1c , weight, BMI, eGFR and cholesterol, compared with baseline) were recorded and analysed from 3 months to 3 years post index date
Lancet 2019, 394(10193): 121-130
Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, pancreatitis history, severe GI or kidney disease, pregnancy, and breastfeeding
What about food noise
Maximize healthy, sustainable weight loss through nourishing food choices
